Abstract Details

Title A History of Non Oral Treatments For Management of Headache

Topic Research Methodology, �鶹��ýӳ��, and History

Presentation(s) P7 - Poster Session 7 (5:30 PM-6:30 PM)

Poster/Presentation
Number 6-002

Objective To review the history of the pharmacological treatment of migraine with regards to non oral forms and how those treatments remain relevant in today’s pharmacopeia.

Background The pharmacological treatment of migraine extends beyond simple pills and capsules. Since the 19th century or earlier, individuals have used catarrhs, vinegars/ smelling salts, nasal sprays and powders as well as ointments or plasters, eye drops and ear drops, suppositions and intravenous treatments. Many of these treatment options remain relevant and in common usage today.

Design/Methods A review of the literature of the history of headache remedies was undertaken. Special attention was paid on non oral treatments, their derivations and any continued relevance. When available, actual examples of these remedies were examined so as to determine usage. The remedies were organized as per method of use and, secondarily, drug class.

Results Over the last 150 years there have been hundreds of headache remedies which have now become obsolete. While most pharmacological interventions may be oral, a number of them are non oral, utilizing other routes of administration. Amongst common treatments there are a range of routes of administration including nasal, rectal, transdermal and cross ear or eye or directly intravenously. Each of these routes has benefits and draw backs, and may not be as maximally utilized as they could be.

Conclusions Many patients with migraine suffer from nausea and vomiting, gastroparesis and comorbid conditions that affect the GI tract. Many of these individuals may benefit from non oral routes of administration for acute treatment. By reviewing previously used remedies, we hope to reflect upon past and current treatment while considering modern innovations.

Authors/Disclosures
Noah Rosen, MD, F�鶹��ýӳ�� PRESENTER	Dr. Rosen has received personal compensation for serving as an employee of Northwell Health. An immediate family member of Dr. Rosen has received personal compensation for serving as an employee of New York University. Dr. Rosen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/ Abbvie. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Rosen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer . Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Rosen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/ Abbvie. Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pfizer. Dr. Rosen has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer.
Robert A. Duarte, MD (Northwell)	Dr. Duarte has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for LILLY . Dr. Duarte has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan . Dr. Duarte has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LILLY . Dr. Duarte has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for LILLY . Dr. Duarte has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan. Dr. Duarte has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Duarte has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for HPMB.